Latest

Learn how HLA-DR and CD38 flow cytometry measures activated T cells, what high results may mean, why ranges vary, and how clinicians plan follow-up.

Activated T-Cell Marker Test: HLA-DR, CD38, Immune Activation, and Inflammation

Understand how CD19 and CD20 B-cell counts are measured, why results may be high or low, how anti-CD20 therapy affects them, and which follow-up tests assess antibody function.

B-Cell Count Test: CD19, CD20, Immune Function, and Antibody Production

Learn what a CD4 count measures, how HIV affects helper T cells, what common ranges and thresholds mean, why results fluctuate, and how the test guides monitoring and infection prevention.

CD4 Count Test: Helper T Cells, Immune Function, HIV Monitoring, and Meaning

Learn how the CD4/CD8 ratio is calculated, what low or high results may mean, why an inverted ratio is nonspecific, and how the test adds context in HIV and immune monitoring.

CD4/CD8 Ratio Test: Immune Balance, High and Low Ratio, and Meaning

Learn what a CD8 count measures, why cytotoxic T-cell numbers may rise or fall, how viral infections affect results, and why cell quantity does not equal antiviral function.

CD8 Count Test: Cytotoxic T Cells, Immune Function, and Viral Response

Understand what a chemokine panel measures, why immune-signaling and cell-migration markers rise or fall, and how specialists interpret patterns and limitations.

Chemokine Panel Test: Immune Signaling, Inflammation, and Cell Migration Markers

Diagnostics

Home Diagnostics Page 33

Understand HER2 and ERBB2 testing in breast, gastric, lung, and other cancers, including IHC, ISH, mutations, targeted therapy, and result interpretation.

HER2/ERBB2 Test: Breast, Gastric, Lung Cancer, and Targeted Therapy Results

Learn how hereditary cancer genetic panels test multiple risk genes, who should be tested, what positive, negative, and VUS results mean, and how findings guide care.

Hereditary Cancer Genetic Panel Test: Cancer Risk Genes and Results

Learn how IDH1 and IDH2 mutation testing guides diagnosis and treatment in glioma, AML, and cholangiocarcinoma, including positive, negative, and targeted therapy results.

IDH1 and IDH2 Mutation Test: Brain Cancer, Leukemia, Cholangiocarcinoma, and Results

Learn how JAK2 mutation testing supports diagnosis of polycythemia vera, essential thrombocythemia, and myelofibrosis and how positive, negative, and low-level results are interpreted.

JAK2 Mutation Test: Myeloproliferative Neoplasm, Blood Cancer, and Results

Learn how KIT mutation testing guides GIST therapy, identifies selected melanoma targets, supports systemic mastocytosis diagnosis, and clarifies positive, negative, and low-level results.

KIT Mutation Test: GIST, Melanoma, Mast Cell Disease, and Results

Learn how KRAS mutation testing guides treatment in colorectal, lung, and pancreatic cancer and how to interpret G12C, other variants, negative results, and repeat testing.

KRAS Mutation Test: Colon, Lung, Pancreatic Cancer, and Results

Learn how liquid biopsy and ctDNA testing find tumor mutations, guide targeted therapy, assess resistance and MRD, and why negative or low-level plasma results need careful interpretation.

Liquid Biopsy Cancer Test: ctDNA, Tumor Mutations, and Results

Learn how Lynch syndrome testing for MLH1, MSH2, MSH6, PMS2, and EPCAM works, how tumor screening differs from germline testing, and what positive, negative, and uncertain results mean.

Lynch Syndrome Genetic Test: MLH1, MSH2, MSH6, PMS2, EPCAM, and Results

Learn how MEN1 genetic testing confirms multiple endocrine neoplasia type 1, who should be tested, what positive and negative results mean, and how surveillance protects patients and relatives.

MEN1 Genetic Test: Multiple Endocrine Neoplasia Type 1 and Results

Learn how MET exon 14 skipping testing finds an actionable lung cancer driver, why DNA and RNA methods differ, and how positive, negative, plasma, treatment, and resistance results are interpreted.

MET Exon 14 Skipping Test: Lung Cancer, Targeted Therapy, and Results

Learn how MSI and dMMR testing guides cancer immunotherapy and Lynch syndrome evaluation, including IHC patterns, PCR, NGS, reflex testing, and discordant results.

Microsatellite Instability (MSI) and Mismatch Repair Deficiency (dMMR) Test: Cancer Immunotherapy,...

Learn how minimal residual disease (MRD) tests detect tiny amounts of cancer, what positive and negative results mean, and how testing may guide recurrence risk and follow-up.

Minimal Residual Disease (MRD) Test: Cancer Recurrence Risk and Results

Learn what an MLH1 genetic test shows, how results relate to Lynch syndrome and colon cancer risk, and what positive, negative, and uncertain findings mean for care and family.

MLH1 Genetic Test: Lynch Syndrome, Colon Cancer Risk, and Results

Learn how the MPL mutation test helps evaluate high platelets and myeloproliferative neoplasms, including positive, negative, VAF, treatment, and follow-up results.

MPL Mutation Test: Myeloproliferative Neoplasm, Platelets, and Results

Learn what an MSH2 genetic test shows, how results relate to Lynch syndrome and colon cancer risk, and what positive, negative, and uncertain findings mean for care and family.

MSH2 Genetic Test: Lynch Syndrome, Colon Cancer Risk, and Results

Learn what an MSH6 genetic test shows, how results relate to Lynch syndrome and colon cancer risk, and what positive, negative, and uncertain findings mean for care and family.

MSH6 Genetic Test: Lynch Syndrome, Colon Cancer Risk, and Results

Learn how MUTYH genetic testing identifies polyposis risk, why two variants differ from one, and what positive, negative, carrier, and uncertain results mean.

MUTYH Genetic Test: Colon Polyposis, Cancer Risk, and Results

Understand MYC rearrangement test results in lymphoma and leukemia, including FISH, double-hit and triple-hit findings, double expression, prognosis, and treatment implications.

MYC Rearrangement Test: Lymphoma, Leukemia, and Results

Learn how MYD88 mutation testing supports Waldenström macroglobulinemia and lymphoma diagnosis, including L265P results, methods, treatment relevance, and limits.

MYD88 Mutation Test: Waldenstrom Macroglobulinemia, Lymphoma, and Results

Learn how NPM1 mutation testing classifies AML, affects prognosis, and supports sensitive MRD monitoring, including positive, negative, VAF, and treatment results.

NPM1 Mutation Test: AML Prognosis, Leukemia Genetics, and Results

1...323334...74 Page 33 of 74